器官晶片市场类型[产品（肝臟、肺臟、心臟、肾臟）、服务]、材料（PDMS、聚合物、玻璃）、模型类型（单一、多重器官）、应用（药物发现、毒性测试、个人化医疗） ，最终用户，全球预测2024-2032

由于对动物试验替代品的需求不断增长、技术进步以及研发投资不断增加，预计 2024 年至 2032 年全球器官晶片市场的CAGR将超过 32.2%。

据善待动物组织 (PETA) 称，英国各地对动物进行了近 7,600 万次手术。随着组织的目标是减少这一数字并儘量减少对动物测试的依赖，预计市场将会成长。器官晶片为模仿人体器官的生理和机械特性提供了一个有前途的平台，有助于彻底改变药物开发、毒性测试和疾病建模。

器官晶片市场根据类型、材料、模型类型、应用、最终用户和地区进行分类。

由于其多功能性、生物相容性和可调特性，预计聚合物材料领域从 2024 年到 2032 年将录得强劲的CAGR。聚二甲基硅氧烷（PDMS）和聚氨酯等聚合物由于能够有效复製人体组织的微环境，已成为製造器官晶片的热门选择。此外，包括软光刻和微流体在内的聚合物製造技术的进步，进一步推动了基于聚合物的器官晶片平台在製药和生物技术行业的采用。

毒性测试应用领域预计到 2032 年将产生大量收入，因为它们提供了比传统动物测试方法更准确和更具预测性的替代方案。这些微流体装置使研究人员能够模拟药物、化学物质和人体组织之间的复杂相互作用，从而促进潜在毒性问题的早期检测并最大限度地减少对动物模型的依赖。随着世界各地监管机构强调在药物开发中减少和取代动物测试，预计未来几年对用于毒性测试的器官晶片的需求将激增。

在领先製药公司、学术研究机构和支持性监管框架的推动下，到 2032 年，欧洲器官晶片市场规模将大幅扩大。英国、德国和法国正在大力投资加速研究和商业化工作。此外，欧洲药品管理局（EMA）等监管机构为促进采用替代检测方法而采取的倡议正在促进晶片器官平台在该地区的广泛接受。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性病盛行率增加
    • 对个人化医疗的需求不断增加
    • 器官晶片技术的不断进步
    • 扩大器官晶片模型在生物医学应用的使用
  • 产业陷阱与挑战
    • 实施器官晶片技术的挑战与复杂性
    • 监管障碍
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪錶板

第 5 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 产品
  • 肝臟晶片
  • 肺晶片
  • 晶片上的心臟
  • 肾臟晶片
  • 其他产品
• 服务

第 6 章：市场估计与预测：按材料划分，2018 - 2032 年

• 主要趋势
• 聚二甲基硅氧烷 (PDMS)
• 聚合物
• 玻璃

第 7 章：市场估计与预测：按车型类型，2018 年 - 2032 年

• 主要趋势
• 单一器官模型
• 多重器官模型

第 8 章：器官晶片市场估计与预测：按应用，2018 年 - 2032 年

• 主要趋势
• 药物发现
• 毒性测试
• 疾病建模
• 个人化医疗
• 其他应用

第 9 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

• 主要趋势
• 製药和生物技术公司
• 学术及研究机构
• 其他最终用户

第 10 章：器官晶片市场估计与预测：按地区，2018 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 11 章：公司简介

• Altis Biosystems
• AlveoliX AG
• Axosim
• Bi/ond Solutions B.V
• Cherry Biotech
• CN-Bio
• Emulate, Inc.
• Hesperos, Inc.
• Insphero
• MesoBioTech
• Mimetas B.V.
• Nortis Inc.
• React4Life
• TARA Biosystems (Valo Health)
• TissUse GmbH

The global organs-on-chips market is anticipated to witness more than 32.2% CAGR from 2024 to 2032 driven by the increasing demand for alternatives to animal testing, advancements in technology, and rising investments in R&D.

According to PETA, nearly 76 million procedures are done on animals across the UK. As organizations aim to reduce this number and minimize the dependency on animal testing, the market is anticipated to grow. As organs-on-chips offer a promising platform for mimicking the physiological and mechanical properties of human organs, thus helping in revolutionizing drug development, toxicity testing, and disease modeling.

The organs-on-chips market is classified based on type, material, model type, application, end-user, and region.

The polymer material segment is predicted to record strong CAGR from 2024 to 2032, owing to its versatility, biocompatibility, and tunable properties. Polymers such as polydimethylsiloxane (PDMS) and polyurethane have emerged as popular choices for manufacturing organs-on-chips due to their ability to replicate the microenvironment of human tissues effectively. Moreover, advancements in polymer fabrication techniques, including soft lithography and microfluidics, are further fueling the adoption of polymer-based organs-on-chips platforms across pharmaceutical and biotechnology industries.

The toxicity testing application segment is expected to generate massive revenue by 2032 as they offer a more accurate and predictive alternative to traditional animal testing methods. These microfluidic devices enable researchers to simulate the complex interactions between drugs, chemicals, and human tissues, thereby facilitating early detection of potential toxicity issues and minimizing the reliance on animal models. With regulatory agencies worldwide emphasizing the reduction and replacement of animal testing in drug development, the demand for organs-on-chips for toxicity testing is expected to surge in the coming years.

Europe organs-on-chips market size will expand significantly through 2032 driven by the presence of leading pharmaceutical companies, academic research institutes, and supportive regulatory frameworks. United Kingdom, Germany, and France are significantly investing to accelerate research and commercialization efforts. Additionally, initiatives by regulatory bodies such as the European Medicines Agency (EMA) to promote the adoption of alternative testing methods are fostering the widespread acceptance of organs-on-chips platforms across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data validation
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic disease
    • 3.2.1.2 Increasing demand for personalized medicine
    • 3.2.1.3 Growing advancement in organ-on-chip technology
    • 3.2.1.4 Expanding use of organ-on-chip models in biomedical applications
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Challenges and intricacies in implementing organ-on-chip techniques
    • 3.2.2.2 Regulatory obstacles
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Product
  • 5.2.1 Liver-on-chip
  • 5.2.2 Lung-on-chip
  • 5.2.3 Heart-on-chip
  • 5.2.4 Kidney-on-chip
  • 5.2.5 Other products
• 5.3 Service

Chapter 6 Market Estimates and Forecast, By Material, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Polydimethylsiloxane (PDMS)
• 6.3 Polymer
• 6.4 Glass

Chapter 7 Market Estimates and Forecast, By Model Type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Single-organ model
• 7.3 Multi-organ model

Chapter 8 Organ on Chip Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Drug discovery
• 8.3 Toxicity testing
• 8.4 Disease modeling
• 8.5 Personalized medicine
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End-User, 2018 - 2032 (USD Million)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology companies
• 9.3 Academic and research institutes
• 9.4 Other end-users

Chapter 10 Organ on Chip Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Altis Biosystems
• 11.2 AlveoliX AG
• 11.3 Axosim
• 11.4 Bi/ond Solutions B.V
• 11.5 Cherry Biotech
• 11.6 CN-Bio
• 11.7 Emulate, Inc.
• 11.8 Hesperos, Inc.
• 11.9 Insphero
• 11.10 MesoBioTech
• 11.11 Mimetas B.V.
• 11.12 Nortis Inc.
• 11.13 React4Life
• 11.14 TARA Biosystems (Valo Health)
• 11.15 TissUse GmbH